AR067780A1 - Compuestos de bicicloactama sustituida - Google Patents
Compuestos de bicicloactama sustituidaInfo
- Publication number
- AR067780A1 AR067780A1 ARP080103360A ARP080103360A AR067780A1 AR 067780 A1 AR067780 A1 AR 067780A1 AR P080103360 A ARP080103360 A AR P080103360A AR P080103360 A ARP080103360 A AR P080103360A AR 067780 A1 AR067780 A1 AR 067780A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently
- compounds
- perfluoroalkoxy
- tautomer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229920001774 Perfluoroether Polymers 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- -1 cyano, hydroxyl Chemical group 0.000 abstract 1
- 125000005724 cycloalkenylene group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos y composiciones farmacéuticas que los contienen, compuestos utiles para tratar la hipertension la enfermedad arterial coronaria la hiper-lipidemia, apoplejía y diabetes Reivindicacion 1: Un compuesto que tiene la formula 1 o un tautomero del mismo, o una sal farmacéuticamente aceptable de dicho compuesto o tautomero, en la que: (a) R1 es H -alquilo (C1-4), -perfluoroalquilo (C1-4), -perfluoroalcoxi (C1-4), o -alcoxi (C1-4); (b) R2 y R3, tomados por separado, son independientemente H, -alquilo (C1-4), o -perfluoroalquilo (C1-4); o R2 y R3, tomados junto con el carbono al que están unidos, es -cicloalquilo (C3-6); (c) R4 es H o -alquilo (C1-4); (d) cada uno de R5a, R5b, RSc y R5d es independientemente H, F, CI, Br, -alquilo (C1-4), -OH o -O-alquilo (C1-4); (e) Q es -O- o un enlace; (f) A es un grupo -cicloalquileno (C3-6), un grupo -cicloalquenileno (C3-6) o fenileno; (g) Z es-C(R6a)(R6b)- o un enlace donde cada R6a y R6b es independientemente -H o -alquilo (C1-4), o R6a y R6b, tomados junto con el carbono al que están unidos, es un -cicloalquilo (C3-6); (h) R7 es C(O)R8, ciano, hidroxilo, -alcoxi (C1-4), -perfluoroalcoxi (C1-4) o un mimético de ácido carboxílico; (i) R8 es -OR9 o NHR10; (j) R9 es -H, -alquilo (C1-4), o -perfluoroalquilo (C1-4); y (k) R10 es -H, -alquilo (C1-4), tetrazolilo o S(O)2CF3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95350707P | 2007-08-02 | 2007-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067780A1 true AR067780A1 (es) | 2009-10-21 |
Family
ID=39926534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103360A AR067780A1 (es) | 2007-08-02 | 2008-08-01 | Compuestos de bicicloactama sustituida |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20090036425A1 (es) |
| EP (1) | EP2185567B1 (es) |
| JP (1) | JP4629808B2 (es) |
| KR (1) | KR20100032443A (es) |
| CN (1) | CN101772504A (es) |
| AP (1) | AP2010005163A0 (es) |
| AR (1) | AR067780A1 (es) |
| AT (1) | ATE502948T1 (es) |
| AU (1) | AU2008281545B2 (es) |
| BR (1) | BRPI0815067A2 (es) |
| CA (1) | CA2695291C (es) |
| CL (1) | CL2008002227A1 (es) |
| CO (1) | CO6251365A2 (es) |
| CR (1) | CR11223A (es) |
| CY (1) | CY1111628T1 (es) |
| DE (1) | DE602008005757D1 (es) |
| DK (1) | DK2185567T3 (es) |
| DO (1) | DOP2010000046A (es) |
| EA (1) | EA201000050A1 (es) |
| EC (1) | ECSP109932A (es) |
| ES (1) | ES2361716T3 (es) |
| HN (1) | HN2008001191A (es) |
| HR (1) | HRP20110335T1 (es) |
| MA (1) | MA31580B1 (es) |
| PA (1) | PA8791601A1 (es) |
| PE (1) | PE20090897A1 (es) |
| PL (1) | PL2185567T3 (es) |
| PT (1) | PT2185567E (es) |
| SI (1) | SI2185567T1 (es) |
| TN (1) | TN2010000053A1 (es) |
| TW (1) | TWI356059B (es) |
| UA (1) | UA94833C2 (es) |
| WO (1) | WO2009016462A2 (es) |
| ZA (1) | ZA201000255B (es) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007007101A (es) | 2004-12-14 | 2007-08-21 | Astrazeneca Ab | Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa. |
| EP1966221A1 (en) | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
| EP2402318A1 (en) | 2006-03-31 | 2012-01-04 | Novartis AG | DGAT inhibitors |
| US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
| BRPI0712823A2 (pt) | 2006-06-23 | 2012-07-24 | Abbott Lab | derivados de ciclopropil amina como moduladores de receptor de histamina h3 |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| TW201038580A (en) * | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| TW201040174A (en) * | 2009-02-03 | 2010-11-16 | Pfizer | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives |
| TW201040175A (en) * | 2009-02-04 | 2010-11-16 | Pfizer | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives |
| DK3366686T3 (da) | 2009-03-20 | 2020-11-23 | Metabasis Therapeutics Inc | Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| DK2547679T3 (en) | 2010-03-19 | 2016-01-11 | Pfizer | 2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| CA2815169C (en) | 2010-10-29 | 2015-10-06 | Pfizer Inc. | N1/n2-lactam acetyl-coa carboxylase inhibitors |
| WO2012112364A1 (en) * | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Lactam derivatives as dgat-1 inhibitors |
| WO2012122075A1 (en) * | 2011-03-08 | 2012-09-13 | Merck Sharp & Dohme Corp. | Lactam derivatives as dgat-1 inhibitors |
| GEP20166474B (en) | 2011-04-22 | 2016-05-10 | Pfizer | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors |
| TWI577670B (zh) | 2011-05-10 | 2017-04-11 | 基利科學股份有限公司 | 充當離子通道調節劑之稠合雜環化合物 |
| KR101919080B1 (ko) * | 2011-05-20 | 2018-11-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
| EP2731944A1 (en) | 2011-07-15 | 2014-05-21 | Pfizer Inc | Gpr 119 modulators |
| CN103732578B (zh) | 2011-07-22 | 2015-08-12 | 辉瑞大药厂 | 喹啉基胰高血糖素受体调节剂 |
| EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013068439A1 (en) * | 2011-11-09 | 2013-05-16 | Intervet International B.V. | 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
| CA2853024C (en) | 2011-11-11 | 2017-08-22 | Pfizer Inc. | 2-thiopyrimidinones |
| US9271969B2 (en) | 2012-02-07 | 2016-03-01 | Kainos Medicine, Inc. | Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| WO2013150416A1 (en) | 2012-04-06 | 2013-10-10 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| RU2014147220A (ru) * | 2012-04-25 | 2016-06-10 | Корея Рисерч Инститьют Оф Кемикал Текнолоджи | Новое бета-аланиновое производное, его фармацевтически приемлемые соли и фармацевтическая композиция, включающая его в качестве активного ингредиента |
| ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
| HK1206341A1 (en) | 2012-06-20 | 2016-01-08 | 霍夫曼-拉罗奇有限公司 | Substituted pyrazole compounds as lpar antagonists |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2014054053A1 (en) | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| EA031114B1 (ru) * | 2012-11-23 | 2018-11-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | ПРОИЗВОДНЫЕ ДИГИДРОПИРИМИДО[5,4-f]ОКСАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ДИАЦИЛГЛИЦЕРИН АЦИЛТРАНСФЕРАЗЫ |
| CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
| JP2016507551A (ja) | 2013-02-13 | 2016-03-10 | ファイザー・インク | ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014140241A1 (en) * | 2013-03-15 | 2014-09-18 | Intervet International B.V. | Pyridine derivatives as dgat-1 inhibitors |
| CN104418866B (zh) * | 2013-08-23 | 2018-10-16 | 青岛黄海制药有限责任公司 | Dgat1抑制剂及其制备方法和用途 |
| EP3055300B1 (en) | 2013-10-09 | 2018-03-07 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| KR101772836B1 (ko) | 2014-03-17 | 2017-08-29 | 화이자 인코포레이티드 | 대사 및 관련 장애의 치료에 사용하기 위한 디아실글리세롤 아실트랜스퍼라제 2 억제제 |
| BR112016023117B1 (pt) | 2014-04-04 | 2023-02-07 | Pfizer Inc | Compostos de heteroarila ou arila bicíclicos fundidos |
| KR20180078347A (ko) | 2014-04-10 | 2018-07-09 | 화이자 인코포레이티드 | 2-아미노-6-메틸-4,4a,5,6-테트라히드로피라노[3,4-d][1,3]티아진-8a(8H)-일-1,3-티아졸-4-일 아미드 |
| WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
| WO2016103097A1 (en) | 2014-12-22 | 2016-06-30 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
| JP2018515480A (ja) | 2015-05-05 | 2018-06-14 | ファイザー・インク | ２−チオピリミジノン |
| JP2018516254A (ja) | 2015-05-29 | 2018-06-21 | ファイザー・インク | バニン１酵素の阻害薬としての新規なヘテロ環化合物 |
| TN2017000485A1 (en) | 2015-06-17 | 2019-04-12 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| AU2016305590A1 (en) | 2015-08-13 | 2018-02-15 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds |
| KR102029124B1 (ko) | 2015-08-27 | 2019-10-07 | 화이자 인코포레이티드 | Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물 |
| WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド |
| EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| CN108473469B (zh) | 2015-12-29 | 2020-11-03 | 辉瑞公司 | 作为己酮糖激酶抑制剂的被取代的3-氮杂双环[3.1.0]己烷 |
| EP3484876A1 (en) | 2016-07-14 | 2019-05-22 | Pfizer Inc | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN108164548B (zh) * | 2016-12-07 | 2020-09-08 | 四川大学 | 嘧啶并吗啉衍生物及其制备方法和用途 |
| WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| BR112021003039A2 (pt) | 2018-08-31 | 2021-05-18 | Pfizer Inc. | combinações para o tratamento de nash/nafld e doenças relacionadas |
| WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| WO2020234726A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| US20220363673A1 (en) | 2019-06-28 | 2022-11-17 | Pfizer Inc. | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| PL4097099T3 (pl) | 2020-02-07 | 2024-11-04 | Gasherbrum Bio, Inc. | Heterocykliczne agonisty glp-1 |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| US20250066337A1 (en) | 2021-08-26 | 2025-02-27 | Pfizer Inc. | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide |
| WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
| JP2025513071A (ja) | 2022-04-14 | 2025-04-22 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| IL319486A (en) | 2022-10-07 | 2025-05-01 | Pfizer | HSD17B13 Inhibitors and/or Retarders |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| EP4634180A1 (en) | 2022-12-15 | 2025-10-22 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| CN120731201A (zh) | 2022-12-16 | 2025-09-30 | 辉瑞公司 | 含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ533540A (en) * | 2002-01-18 | 2006-04-28 | Kyorin Seiyaku Kk | Fused bicyclic pyrimidine derivatives that act as effective tachykinin receptor antagonists such as NK1 to treat tachykinin receptor-related pathological conditions |
| KR100772297B1 (ko) * | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
| JP2007519605A (ja) * | 2004-01-30 | 2007-07-19 | 日本たばこ産業株式会社 | 食欲抑制薬 |
| JP2006056881A (ja) * | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
| EP1966221A1 (en) * | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
-
2008
- 2008-07-17 US US12/174,820 patent/US20090036425A1/en not_active Abandoned
- 2008-07-22 SI SI200830242T patent/SI2185567T1/sl unknown
- 2008-07-22 DE DE602008005757T patent/DE602008005757D1/de active Active
- 2008-07-22 EA EA201000050A patent/EA201000050A1/ru unknown
- 2008-07-22 JP JP2010518764A patent/JP4629808B2/ja not_active Expired - Fee Related
- 2008-07-22 AP AP2010005163A patent/AP2010005163A0/en unknown
- 2008-07-22 PT PT08788942T patent/PT2185567E/pt unknown
- 2008-07-22 CN CN200880101674A patent/CN101772504A/zh active Pending
- 2008-07-22 HR HR20110335T patent/HRP20110335T1/hr unknown
- 2008-07-22 WO PCT/IB2008/001963 patent/WO2009016462A2/en not_active Ceased
- 2008-07-22 DK DK08788942.4T patent/DK2185567T3/da active
- 2008-07-22 PL PL08788942T patent/PL2185567T3/pl unknown
- 2008-07-22 UA UAA201001078A patent/UA94833C2/ru unknown
- 2008-07-22 ES ES08788942T patent/ES2361716T3/es active Active
- 2008-07-22 CA CA2695291A patent/CA2695291C/en not_active Expired - Fee Related
- 2008-07-22 AU AU2008281545A patent/AU2008281545B2/en not_active Expired - Fee Related
- 2008-07-22 BR BRPI0815067-2A2A patent/BRPI0815067A2/pt not_active IP Right Cessation
- 2008-07-22 AT AT08788942T patent/ATE502948T1/de active
- 2008-07-22 KR KR1020107002273A patent/KR20100032443A/ko not_active Ceased
- 2008-07-22 EP EP08788942A patent/EP2185567B1/en active Active
- 2008-07-29 CL CL2008002227A patent/CL2008002227A1/es unknown
- 2008-07-29 HN HN2008001191A patent/HN2008001191A/es unknown
- 2008-07-30 PA PA20088791601A patent/PA8791601A1/es unknown
- 2008-08-01 PE PE2008001299A patent/PE20090897A1/es not_active Application Discontinuation
- 2008-08-01 AR ARP080103360A patent/AR067780A1/es not_active Application Discontinuation
- 2008-08-01 TW TW097129254A patent/TWI356059B/zh not_active IP Right Cessation
-
2009
- 2009-01-22 US US12/357,544 patent/US7718645B2/en not_active Expired - Fee Related
-
2010
- 2010-01-13 ZA ZA2010/00255A patent/ZA201000255B/en unknown
- 2010-01-18 CR CR11223A patent/CR11223A/es not_active Application Discontinuation
- 2010-01-29 TN TNP2010000053A patent/TN2010000053A1/fr unknown
- 2010-02-01 DO DO2010000046A patent/DOP2010000046A/es unknown
- 2010-02-01 CO CO10010179A patent/CO6251365A2/es not_active Application Discontinuation
- 2010-02-02 EC EC2010009932A patent/ECSP109932A/es unknown
- 2010-02-02 MA MA32575A patent/MA31580B1/fr unknown
-
2011
- 2011-05-17 CY CY20111100479T patent/CY1111628T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067780A1 (es) | Compuestos de bicicloactama sustituida | |
| AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| CO6140024A2 (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer | |
| MX373153B (es) | Derivados de diazacarbazol como ligandos de tau para tomografía por emisión de positrones (pet). | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| CL2011003192A1 (es) | Acido (2s)-3-(2-fluoro-5-(5-fluoro-1h-pirrolo[2,3-b]piridin-3-il)fenilamino)biciclo[2.2.2]octano-2-carboxilico; metodo para prepararlo; composicion farmaceutica que lo comprende; y su uso en el tratamiento de la influenza; metodo para reducir el virus de la influenza in vitro. | |
| CL2008002995A1 (es) | Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih. | |
| AR094588A2 (es) | Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica | |
| AR073701A1 (es) | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. | |
| AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| ECSP088821A (es) | Derivados de tioxantina y su uso como inhibidores de la mpo | |
| CL2011001586A1 (es) | Metodo que comprende una composicion que contiene sulfoximida de 6-haloalquilpiridin-3-il-alquilo n-sustituida; composicion comprendiendo una mezcla estereoisomera de dicha sulfoximida en una formulacion farmaceutica acuosa. | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| CO6260089A2 (es) | Activadores de guanilato ciclasas solubles | |
| AR083817A1 (es) | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide | |
| AR080590A1 (es) | Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2 | |
| AR063637A1 (es) | Inhibidores de las quinasas y metodos para su utilizacion | |
| PE20091671A1 (es) | Compuestos antivirales, composiciones y metodos para usarlos | |
| CL2008002089A1 (es) | Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto. | |
| AR077969A1 (es) | Derivados de (tio)morfolina comomoduladores de s1p | |
| AR061894A1 (es) | Vacunas para malaria | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| ES2409404T3 (es) | Compuestos heterocíclicos de fenoximetilo | |
| AR117640A1 (es) | Compuestos de 2,6-diaminopiridina como inhibidores de khk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |